KR20220021237A - Composition for preventing and treating Bowel diseases caused by fine dust containing Ecklonia cava extract - Google Patents

Abstract

The present invention relates to a composition for preventing, ameliorating, and treating a fine dust-attributable bowel disease, which contains an ecklonia cava extract as an active ingredient. The present invention has been completed based on the confirmation that the ecklonia cava extract ameliorates a laboratory animal's reduced weight and feed amount attributable to ultrafine dust and the ecklonia cava extract improves an intestinal function. The present invention can be useful as a health functional food composition for preventing and ameliorating an ultrafine dust-attributable bowel disease, a food composition for preventing and ameliorating an ultrafine dust-attributable bowel disease, a pharmaceutical composition for preventing and treating an ultrafine dust-attributable bowel disease, or a cosmetic composition for preventing and ameliorating an ultrafine dust-attributable bowel disease.

Description

Composition for preventing and treating Bowel diseases caused by fine dust containing Ecklonia cava extract including Ecklonia cava extract

The present invention relates to a composition for preventing, improving and treating intestinal diseases caused by fine dust comprising an Ecklonia cava extract as an active ingredient. More specifically, it relates to a composition for use in improving intestinal function through the prevention, improvement, and treatment of intestinal diseases among intestinal diseases caused by ultrafine dust, including the Ecklonia cava extract.

The present invention relates to a composition for preventing, improving and treating intestinal diseases caused by fine dust comprising an Ecklonia cava extract as an active ingredient, and more specifically, among intestinal diseases caused by ultrafine dust containing an Ecklonia cava extract It relates to a composition for use in improving intestinal function through the prevention, amelioration and treatment of intestinal diseases. Examples of the intestinal disease include irritable bowel syndrome, Crohn's disease, ulcerative colitis, chronic constipation, and short bowel syndrome.

On the other hand, as the concentration of particulate matter (PM) increases and the duration thereof increases, interest in the human body effect by fine dust is increasing (Kim et al., 2017). Fine dust has been with Korea for a long time, and since ancient times, it has been affected by yellow dust originating from the desert regions of Mongolia and China and the Huanghua River basin. reported (Myung, 2016).

Ultrafine dust (PM _2.5 ) refers to fine dust with an aerodynamic diameter of 2.5 μm or less, and secondary air pollutants (NO ₃ ^- , SO ₄ ^- , NH4 ^- , polyacromatichydrocarbon (PAH), quinone, etc.) are predominant (Kim et al., 2017). According to the World Health Organization (World Health Organization, 2013), long-term exposure to PM ₁₀ (fine dust with an aerodynamic diameter of 10 μm or less) increases respiratory tract-related diseases and mortality, with PM _2.5 being a stronger risk factor. reported to act as

Dust with a diameter of 5-10 μg/m ³ or less can be absorbed into the body through the nasal mucosa, 2-5 μg/m ³ or less passes through the respiratory tract, and 0.1-1 μg/m ³ causes alveolar damage. will cause When fine dust is inhaled into the human body, it can be deposited in tissues by various mechanisms such as collision, gravitational sedimentation, diffusion, and electrostatic adsorption, and some circulate throughout the body along with blood.

In particular, it is reported that fine dust deposited in the body induces oxidative stress and inflammatory responses, and causes acute exacerbation of respiratory and circulatory diseases (Myung, 2016). In addition, if it passes through the olfactory epithelial cells, it can reach the brain directly without going through the blood-brain barrier (BBB). It has been reported that by producing -inflammatory cytokines (IL-1, TNF-a and IFN-r), it induces cranial nerve inflammation and further induces cognitive impairment (Block, 2004). Therefore, it is considered that there is a need for research on natural food materials that can suppress oxidative stress and inflammatory responses in the human body that can be induced by fine dust.

On the other hand, Ecklonia cava is a kind of brown algae belonging to the kelp family, and is distributed in temperate coasts such as the Korean Peninsula and Japan, and is abundantly produced on Jeju Island in Korea (Heo et al., 2005). Ecklonia coli contains physiologically active substances such as peptides, polysaccharides, carotenoids, fucoidan and phlorotannins (Wijesinghe and Jeon, 2012).

In particular, phlorotannin, a major physiologically active substance mainly found in brown algae; phlorotannins (eckol, dieckol, 6,6′-bieckol and eckstolonol) are chemical compounds in various industries such as health functional foods and functional cosmetics due to their excellent antioxidant, anti-inflammatory, anti-allergic, wrinkle-generating and hair-promoting effects. It is attracting attention as a substitute (sanjeewa et al., 2016).

In addition, fucoidan, a type of polysaccharide mainly contained in brown algae, is reported to have the effect of suppressing blood lipids and inhibiting the growth of tumor cells, as well as the carboxyl and sulfate groups of polysaccharides having an effect of releasing harmful heavy metals and cations ( Kim et al., 2000). However, despite these various physiologically active functions of seaweed, research on fine dust is very insufficient.

Therefore, in this study, it was confirmed that Ecklonia cava extract improved the reduced body weight and diet of experimental animals due to ultrafine dust, and improved intestinal function. Therefore, it was confirmed that the composition containing the Ecklonia cava extract can be used as a composition for preventing, improving and treating intestinal diseases caused by ultrafine dust, thereby completing the present invention.

Republic of Korea Patent Registration No. 10-1958969

An object of the present invention is to provide a composition for preventing, improving and treating intestinal diseases caused by fine dust comprising an Ecklonia cava extract as an active ingredient in order to solve the above problems, and more specifically, It was confirmed that the Ecklonia cava extract improved the reduced body weight and diet of the experimental animals due to ultrafine dust, and it was confirmed that the intestinal function was improved. Therefore, the present invention was completed by confirming that the composition comprising the E. Ecklonia extract can be used as a composition for preventing, improving and treating intestinal diseases caused by ultrafine dust.

In order to solve the above problems, the present invention provides a health functional food composition for preventing and improving intestinal diseases caused by fine dust, which includes an Ecklonia cava extract as an active ingredient. More preferably, it provides a functional health food composition for preventing and improving intestinal diseases caused by ultrafine dust.

In one embodiment of the present invention, the present invention may use water or may be extracted by an organic solvent extraction method using a volatile solvent, preferably water or 30 to 80% ethanol may be used, but limited thereto it is not going to be

In one embodiment of the present invention, the intestinal disease of the present invention is characterized in that it is a intestinal disease, and the intestinal disease is any one of irritable bowel syndrome, Crohn's disease, ulcerative colitis, chronic constipation, and short bowel syndrome. It can be characterized, but is not limited thereto.

In one embodiment of the present invention, the Ecklonia cava extract may be characterized by increasing the body weight and the amount of food reduced due to exposure to fine dust, but is not limited thereto.

In one embodiment of the present invention, Ecklonia cava extract may be characterized in that it restores the length of the large intestine reduced due to exposure to fine dust, but is not limited thereto.

In one embodiment of the present invention, Ecklonia cava extract may be characterized by reducing the moisture content of the feces increased due to exposure to fine dust, but is not limited thereto.

In one embodiment of the present invention, Ecklonia cava extract may be characterized by changing the microflora of intestinal microflora, but is not limited thereto.

In one embodiment of the present invention, the change in the flora of the intestinal microflora increases the Lactobacillaceae that was reduced due to fine dust, and the Rikenellaceae that was increased due to the fine dust Reduces, fine dust Odoribacteraceae , which was increased due to reducing ( Erysipelotrichaceae ) to reduce, enterobacteriaceae increased due to fine dust ( Enterobacteriaceae ) It may be characterized by reducing, but not limited to, reducing the Eubacteriaceae ( Eubacteriaceae ), which was increased due to fine dust, and reducing the Bacillaceae ( Bacillaceae ) that was increased due to fine dust.

In one embodiment of the present invention, the change in the flora of the intestinal microflora increases the genus Lactobacillus , which was reduced due to fine dust, and Lactobacillaceae_uc , which was reduced due to fine dust, increases, and fine Reducing the genus Aristipes increased due to dust, reducing the genus Pseudoflavonifractor increased due to fine dust, and reducing the genus Odoribacter increased due to fine dust , the genus Sporobacter increased due to fine dust, and the genus Caproic ai producens increased due to fine dust ( Caproiciproducens ) It may be characterized by reducing the genus Escherichia ( Escherichia ), which was increased due to fine dust, but is not limited thereto.

In an embodiment of the present invention, Lactobacillaceae and Lactobacillus are known as major intestinal beneficial bacteria, Escherichia is known as harmful bacteria. On the other hand, there are many other bacteria that are difficult to accurately classify as beneficial bacteria or harmful bacteria. In particular, in this study, the representative strain of Rikenellaceae In the case of the genus Aristipes , although known to increase butyrate, it is a bacteria that has been reported as an intermediate type of bacteria that can act as beneficial or harmful bacteria in various diseases and diseases. This is reported to indicate a difference in expression in various mechanisms, as in the following example. As health-beneficial bacteria, it has been reported to have an improving effect on colitis, autism, liver fiber, and cardiovascular fibrosis, and as health-harmful bacteria, it is reported to cause depression, muscular encephalomyelitis, chronic fatigue syndrome, and colorectal cancer.

In one embodiment of the present invention, Ecklonia cava extract may be characterized by increasing the short-chain fatty acid reduced due to exposure to fine dust, but is not limited thereto.

In addition, the present invention provides a food composition for preventing and improving intestinal diseases caused by fine dust, which includes an Ecklonia cava extract as an active ingredient. More preferably, there is provided a food composition for preventing and improving intestinal diseases caused by ultrafine dust.

In addition, the present invention provides a pharmaceutical composition for preventing and treating intestinal diseases caused by fine dust, comprising an extract extracted from Ecklonia cava as an active ingredient. More preferably, it provides a pharmaceutical composition for preventing and treating intestinal diseases caused by ultrafine dust.

In addition, the present invention provides a cosmetic composition for preventing and improving intestinal diseases caused by fine dust, comprising an Ecklonia cava extract as an active ingredient. More preferably, there is provided a cosmetic composition for preventing and improving intestinal diseases caused by ultrafine dust.

The Ecklonia cava extract of the present invention is excellent in preventing, improving and treating intestinal diseases caused by ultrafine dust, so it is a health functional food composition for preventing and improving intestinal diseases caused by ultrafine dust. It can be usefully used as a food composition for preventing and improving intestinal diseases caused by ultrafine dust, a pharmaceutical composition for preventing and treating intestinal diseases caused by ultrafine dust, or a cosmetic composition for preventing and improving intestinal diseases caused by ultrafine dust .

1 is a diagram showing the effect of the Ecklonia cava extract of the present invention in improving the weight change and dietary amount of experimental animals.
Figure 2 is a diagram showing the effect of the Ecklonia cava extract of the present invention to improve the length of the large intestine and fecal moisture content.
Figure 3 is a diagram showing the significant change (improvement effect) of the intestinal microbial flora of the Ecklonia cava extract of the present invention.
Figure 4 is a diagram showing that the Ecklonia cava extract of the present invention increases the short-chain fatty acids in the feces.
Figure 5 is a diagram analyzing the phenolic compounds of the Ecklonia cava extract of the present invention.

An object of the present invention is to provide a functional health food composition for preventing and improving intestinal diseases caused by fine dust, comprising an extract extracted from Ecklonia cava as an active ingredient. More preferably, it aims to provide a functional health food composition for preventing and improving intestinal diseases caused by ultrafine dust.

In addition, an object of the present invention is to provide a food composition for preventing and improving intestinal diseases caused by fine dust, which includes an Ecklonia cava extract as an active ingredient. More preferably, it aims to provide a food composition for preventing and improving intestinal diseases caused by ultrafine dust.

In addition, an object of the present invention is to provide a pharmaceutical composition for preventing and treating intestinal diseases caused by fine dust, comprising an Ecklonia cava extract as an active ingredient. More preferably, it aims to provide a pharmaceutical composition for preventing and treating intestinal diseases caused by ultrafine dust.

Finally, an object of the present invention is to provide a cosmetic composition for preventing and improving intestinal diseases caused by fine dust, comprising an Ecklonia cava extract as an active ingredient. More preferably, it aims to provide a cosmetic composition for preventing and improving intestinal diseases caused by ultrafine dust.

Hereinafter, the present invention will be described in detail by way of embodiments of the present invention with reference to the accompanying drawings. However, the following embodiments are presented as examples of the present invention, and when it is determined that detailed descriptions of well-known techniques or configurations known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted, , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the scope of equivalents interpreted therefrom and the description of the claims to be described later.

In addition, terms used in this specification are terms used to properly express preferred embodiments of the present invention, which may vary depending on the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part "includes" a certain element, it means that other elements may be further included, rather than excluding other elements, unless otherwise stated.

Throughout this specification, '%' used to indicate the concentration of a specific substance is (w/w) % for solid/solid, (w/v) % for solid/liquid, and Liquid/liquid is (v/v) %.

In one aspect, a health functional food composition for preventing and improving intestinal diseases caused by ultrafine dust, comprising an Ecklonia cava extract as an active ingredient, or food for preventing and improving intestinal diseases due to ultrafine dust, comprising an Ecklonia cava extract as an active ingredient to the composition.

The extract according to the present invention may be obtained by extraction and separation from nature using extraction and separation methods known in the art, and "extract" as defined in the present invention is extracted from Ecklonia cava using an appropriate solvent, For example, crude extracts, polar solvent-soluble extracts, or non-polar solvent-soluble extracts are included. As a suitable solvent for extracting the extract from Ecklonia cava, any food or pharmaceutically acceptable organic solvent may be used, and water or an organic solvent may be used, but is not limited thereto, for example, Purified water, methanol, ethanol, propanol, isopropanol, alcohol having 1 to 4 carbon atoms, including butanol, acetone, ether, benzene (benzene) ), chloroform, ethyl acetate, methylene chloride, hexane, and various solvents such as cyclohexane may be used alone or in combination. As the extraction method, any one of methods such as hot water extraction, cold extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used. In addition, the desired extract may be further subjected to a conventional fractionation process, and may be purified using a conventional purification method.

There is no limitation on the method for preparing the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying the primary extract extracted by the hot water extraction or solvent extraction method described above. In addition, the first extract was further purified using various chromatography methods such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, etc. you may get Therefore, in the present invention, the extract is a concept including all extracts, fractions, and purified products obtained in each step of extraction, fractionation or purification, and their dilutions, concentrates, or dried products.

The food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional food composition in addition to containing the extract as an active ingredient.

Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-mentioned flavoring agents can advantageously use natural flavoring agents (Taumatin), stevia extract (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements. There is this.

In addition, the food composition contains various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, in addition to the active ingredient extract. , alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages.

The health functional food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like. In the present invention, the term 'health functional food composition' refers to a food manufactured and processed using raw materials or ingredients useful for the human body according to Act No. 6727 of the Health Functional Food Act, and It refers to ingestion for the purpose of obtaining useful effects for health purposes, such as regulating nutrients or physiological effects. The health functional food of the present invention may contain normal food additives, and unless otherwise specified, whether it is suitable as a food additive is related to the item according to the general rules and general test method of food additives approved by the Food and Drug Administration. It is judged according to the standards and standards. The items listed in the 'Food Additives Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high pigment, and guar gum; Mixed preparations, such as a sodium L-glutamate preparation, a noodle-added alkali agent, a preservative preparation, and a tar color preparation, etc. are mentioned. For example, the health functional food in the form of a tablet is granulated by a mixture of the active ingredient of the present invention mixed with an excipient, binder, disintegrant and other additives in a conventional manner, followed by compression molding by putting a lubricant, etc., or The mixture can be compression molded directly. In addition, the health functional food in the form of tablets may contain a corrosive agent and the like, if necessary. Among health functional foods in the form of capsules, hard capsules can be prepared by filling a mixture of the active ingredient of the present invention with additives such as excipients in ordinary hard capsules. It can be prepared by filling the mixture mixed with the capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. A health functional food in the form of a ring can be prepared by molding a mixture of the active ingredient of the present invention with an excipient, a binder, a disintegrant, etc. by a known method, and if necessary, it can be coated with sucrose or other skinning agent, Alternatively, the surface may be coated with a material such as starch or talc. The health functional food in the form of granules can be prepared in granular form by a conventionally known method by mixing a mixture of the active ingredient excipients, binders, disintegrants, etc. of the present invention, and may contain flavoring agents, flavoring agents, etc. can

On the other hand, 'gut health' in health functional food is divided into 'improvement through improvement of bowel movement, proliferation of beneficial bacteria, suppression of harmful bacteria, and regulation of immune function'.

In one aspect, it relates to a pharmaceutical composition for preventing and treating intestinal diseases caused by ultrafine dust, comprising an extract extracted from Ecklonia cava as an active ingredient.

The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. The adjuvant may be used without limitation as long as it is known in the art, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase the effect of the present invention.

The pharmaceutical composition according to the present invention may be prepared in a form in which the active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, or sterile injection solutions according to conventional methods, respectively. .

In the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the active ingredient, for example, starch, calcium carbonate, sucrose, lactose, gelatin. It can be prepared by mixing and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. can Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As the base of the suppository, witepsol, tween 61, cacao butter, laurin fat, glycerogelatin, and the like can be used.

The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration can be envisaged, for example, by oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The pharmaceutical composition may be formulated in various oral or parenteral dosage forms.

Formulations for oral administration include, for example, tablets, pills, hard, soft capsules, solutions, suspensions, emulsifiers, syrups, granules, and the like. crose, mannitol, sorbitol, cellulose and/or glycine), lubricants (eg, silica, talc, stearic acid and its magnesium or calcium salts and/or polyethylene glycol). In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and optionally starch, agar, alginic acid. or a disintegrant such as its sodium salt or a boiling mixture and/or absorbent, coloring, flavoring and sweetening agent. The formulation may be prepared by conventional mixing, granulating or coating methods.

In addition, a representative formulation for parenteral administration is an injection formulation, and examples of the solvent for the injection formulation include water, Ringer's solution, isotonic saline, or suspension. The sterile, fixed oil of the injectable preparation may be used as a solvent or suspending medium, and any non-irritating fixed oil including mono- and di-glycerides may be used for this purpose.

In addition, the injection preparation may use a fatty acid such as oleic acid.

In one aspect, it relates to a cosmetic composition for preventing and improving intestinal diseases caused by ultrafine dust, comprising an Ecklonia extract as an active ingredient.

The "cosmetics composition" of the present invention can be prepared by including a cosmetically effective amount of the extract extracted from Ecklonia cava of the present invention and a cosmetically acceptable carrier.

As used herein, the term “cosmetic effective amount” refers to an amount sufficient to achieve skin regeneration efficacy through proliferation of epidermal keratinocytes of the composition of the present invention.

The appearance of the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base. It is available in all formulations suitable for topical application, for example solutions, gels, solids, kneaded dry products, emulsions obtained by dispersing the oily phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or, ionic (liposomes) and It may be provided in the form of a non-ionic vesicular dispersant, or in the form of a cream, skin, lotion, powder, ointment, spray or concealer stick. These compositions can be prepared according to conventional methods in the art. The composition according to the invention can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

The cosmetic composition according to an embodiment of the present invention is not particularly limited in its formulation, for example, softening lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, eye essence, cleansing It can be formulated into cosmetics such as cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil, and body essence.

When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. This can be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydro It may contain a propellant such as carbon, propane/butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene fatty acid esters of glycol, 1,3-butylglycol oil, glycerol fatty esters, polyethylene glycol or sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.

When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate as carrier components , fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative or ethoxylated glycerol fatty acid ester, and the like can be used.

The cosmetic composition of the present invention includes skin, lotion, cream, essence, pack, foundation, color cosmetics, sun cream, two-way cake, face powder, compact, makeup base, skin cover, eye shadow, lipstick, lip gloss, lip fix, eyebrow pencil It can be applied to cosmetics such as , lotion, and detergents such as shampoo and soap.

The cosmetic composition according to an embodiment of the present invention may further include functional additives and components included in general cosmetic compositions in addition to the extract extracted from Ecklonia cava. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extract.

In the cosmetic composition of the present invention, a component contained in a general cosmetic composition may be further blended with the functional additive as needed. Other ingredients included include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation An accelerator, a cooling agent, a limiting agent, purified water, etc. are mentioned.

Hereinafter, the present invention will be described in more detail through examples. However, the above embodiments and experimental examples are presented as examples of the present invention, and when it is determined that detailed descriptions of well-known techniques or configurations known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description will be omitted. , and the present invention is not limited thereto. Various modifications and applications of the present invention are possible within the scope of equivalents interpreted therefrom and the description of the claims to be described later.

[Preparation Example 1] Preparation of Ecklonia cava extract

Ecklonia cava ( E. cava ) used in this experiment was purchased from Jeju City in February 2018 and used. Salt and impurities were removed, dried in a freeze dryer (Ilshin Lab Co., Ltd., Yangju, Korea), and then powdered and stored frozen (-20°C). 1 L of water (distilled water) was added to 20 g of dry powder, followed by extraction at 40°C under reflux cooling for 2 hours. Ecklonia cava extract was filtered through No.2 filter paper (Whatman Inc, Kent, UK) and concentrated using a vacuum concentrator (NN series, EYELA Co., Tokyo, Japan). The concentrated extract was used after freeze-drying.

[Preparation Example 2] Animal Experiment Design

The animals used in this experiment were purchased from 6-week-old male BALB/c mice (Samtako, Osan, Korea), maintained at a temperature of 22±2°C and a relative humidity of 50±5%, and provided with sufficient water and feed. The breeding environment was maintained. All experiments were performed under the approval of Gyeongsang National University Animal Experiment Ethics Committee (IACUC approval number: GNU-180927-M0050). After an acclimatization period for one week, the experimental animals were bred by dividing them into a normal control group (Normal control; NC), an ultrafine dust exposure group (PM _2.5 ), and an Ecklonia cava extract diet group. The ultrafine dust group and the Ecklonia cava extract diet group were exposed to ultrafine dust in the whole body exposure chamber, and the normal control group was injected with filtered air. The E. cava extract diet group (water extract from E. cava ; WEE) was dissolved in drinking water and then orally administered at concentrations of 50, 100, and 200 mg/kg of body weight (WEE 50, WEE 100, WEE 200) before exposure.

[Example 1] Changes in body weight of experimental animals and improvement of diet

The weight and food amount of the experimental animal of Preparation Example 2 were measured once every 4 weeks, and the results of measuring the weight change and the food amount of the experimental animal are shown in FIG. 1 . Due to changes in metabolism in vivo due to exposure to ultrafine dust, statistically significant changes were observed in the PM _2.5 exposure group compared to the normal control group from the 8th week of exposure. In particular, at the 12th week of exposure, the PM _2.5 exposure group (25.71 g, 6.25 g weight gain) showed a relatively reduced body weight compared to the normal control group (29.36 g, 9.06 g weight gain) ( FIGS. 1A and 1B ). The Ecklonia cava extract diet group (WEE 200; 29.14 g, 8.88 g weight gain) was found to have a significant level of protection compared to the normal control group. In addition, at the 12th week of exposure, the PM _2.5 exposure group (3.96 g/day) showed a reduced dietary amount of about 10.81% compared to the normal control group (4.44 g/day) ( FIG. 1c ). The diet of E. Ecklonia extract was found to be restored to the normal control level in WEE 100 (4.28 g/day) and WEE 200 (4.64 g/day).

[Example 2] Effect of improving intestinal function

2.1 Improvement of colon length and fecal water content

The length of the large intestine of the experimental animal of Preparation Example 2 was measured from the colon to the rectum after removing intestinal feces. The moisture content of the feces was measured by measuring the weight of the feces immediately after collection and the feces freeze-dried for 3 days.

In order to confirm changes in the intestinal tract of mice exposed to fine dust, the results of measuring the length of the large intestine and the moisture content of the feces are shown in FIG. 2 . The length of the large intestine was decreased in the PM _2.5 exposed group (8.50 cm, about 11.37% decrease) compared to the normal control group (9.59 cm). On the other hand, the Ecklonia cava extract diet group (WEE 200; 9.57 cm) was found to recover to a significant level compared to the normal control group ( FIGS. 2a and 2b ). The moisture content of the feces showed a tendency to increase in the PM _2.5 exposure group (62.86%) compared to the normal control group (52.07%), and the Ecklonia cava extract diet group (WEE 100; 49.43%, WEE 200; 48.09%) showed an increase compared to the normal control group. It showed a result of reducing to a significant level (Fig. 2c).

2.2 Effect of changing intestinal microflora

For changes in the gut microbiome of the experimental animals of Preparation Example 2, DNA was extracted from frozen feces using a QIAamp DNA stool mini kit (QiagenCanada, Mississauga, ON, Canada). Then, the extracted DNA was analyzed for intestinal flora using next-generation sequencing (NGS) 16S rRNA sequencing. As a result of confirming changes in the intestinal microbial flora, there was no significant change in Phylum (FIG. 3a), but significant changes in Family and Genus were observed.

In the family category, Lactobacillaceae , Muribaculaceae , and Akkermanisiaceae showed a decreasing trend in the fine dust treatment group, and Rikenellaceae and Odoribacter were Odoribacteraceae ), Erysipelotricae ( Erysipelotrichaceae ), Enterobacteriaceae ( Enterobacteriaceae ), Enterococcaceae ( Enterococcaceae ), Eubacteriaceae ( Eubacteriaceae ), Bacillaceae ( Bacillaceae ) were confirmed to exhibit an increased trend ( FIG. 3b and Table 1). In particular, Lactobacillaceae ( Lactobacillaceae ) and Rikenellaceae ( Rikenellaceae ) were confirmed to be the flora significantly changed (improved) by the Ecklonia extract.

Family (Family) control
(Normal control) fine dust treatment
(PM _2.5 exposure) Ecklonia cava extract treatment
(WEE 200) Lactobacillaceae 55.4356±1.0119 ^b 43.3561±0.9525 ^c 72.6258±5.4688 ^a Muribaculaceae 16.4620±2.1509 ^a 8.7859±1.2822 ^b 4.7440±1.4338 ^c Rikenellaceae 2.7872±2.6425 ^ab 5.7041±1.6835 ^a 2.1558 ± 1.1814 ^b Odoribacteraceae 0.3964±0.0267 ^b 1.4420±0.2488 ^a 0.4879±0.0681 ^b Erysipelotrichaceae 0.2301±0.1765 ^b 0.4490±0.1836 ^a 0.1960±0.1294 ^b Enterobacteriaceae 0.02170±0.0222 ^b 0.0597±0.0094 ^a 0.0334±0.0182 ^ab Enterococcaceae 0.0049±0.0016 ^c 0.0093±0.0010 ^b 0.0134±0.0001 ^a Eubacteriaceae 0.0043±0.0025 ^b 0.0441±0.0102 ^a 0.0116±0.0043 ^b Akkermansiaceae 0.0173±0.0023 ^a 0.0155±0.0077 ^ab 0.0012±0.0017 ^b Bacillaceae 0.0000±0.0000 ^b 0.0037±0.0017 ^a 0.0012±0.0017 ^ab

In the genus classification (Genus), the genus Lactobacillus , Lactobacillaceae_uc , Lachnospiraceae_uc , HM 12400_g , and Alistipes , Pseudoflavoni were decreased by exposure to fine dust. Fracto genus ( Pseudoflavonifractor ) , Odoribacter genus ( Odoribacter ) , Sporobacter genus ( Sporobacter ) , Caproic ai producens genus ( Caproiciproducens ) , the genus Escherichia showed an increase ( FIG. 3c and Table 2). In particular, Ecklonia cava extract was shown to increase the Lactobacillus genus ( Lactobacillus ) and Lactobacillaceae_uc, known as representative beneficial bacteria, to a higher level than the normal control group. In addition, the genus Escherichia , known as harmful bacteria, was shown to be reduced. These results indicate that the Ecklonia cava extract (WEE) diet effectively protects the intestinal function from fine dust by increasing beneficial bacteria and reducing harmful bacteria in the intestine.

Genus control
(Normal control) fine dust treatment
(PM _2.5 exposure) Ecklonia cava extract treatment
(WEE 200) Lactobacillus 54.69±1.12 ^b 42.84±1.12 ^c 71.77±5.51 ^a Aliipes 2.78±2.63 ^ab 5.69±1.68 ^a 2.15±1.18 ^b Pseudoflavonifractor 0.46±0.05 ^b 1.59±0.25 ^a 0.58±0.24 ^ab Odoribacter 0.40±0.02 ^b 1.43±0.24 ^a 0.49±0.07 ^b Lactobacillaceae_uc 0.72±0.07 ^a 0.52±0.00 ^b 0.85±0.04 ^a Sporobacter 0.09±0.05 ^b 0.22±0.02 ^a 0.13±0.02 ^b Caproiciproduces 0.04±0.02 ^b 0.26±0.10 ^a 0.07±0.00 ^b Lachnospiraceae_uc 0.16±0.02 ^a 0.07±0.01 ^b 0.02±0.01 ^b HM124200_g 0.61±0.05 ^a 0.29±0.22 ^ab 0.00±0.00 ^b Escherichia 0.02±0.02 ^b 0.06±0.0 ^a 0.03±0.02 ^ab

2.3 Effect of increasing short-chain fatty acids

The frozen feces of the experimental animals of Preparation Example 2 were homogenized using 5 mM NaOH, and then centrifuged (12,000×g for 10 min at 4°C) to obtain a supernatant. 2-ethylbutyric acid, propanol/pyridine (3:2) and propyl chloromate were added to the supernatant, and reacted at room temperature for 1 minute, and this was extracted with hexane and DB-5MS column (5% phenyl methyl siloxane, 30 m × 0.25 mm, thickness 0.25 μm) and GC/MS (GC-MS-TQ 8030 triple quadrupole mass spectrometer, Shimadzu, Kyoto, Japan). The assay conditions were as follows; split ratio 50:1, injection temp 260°C, column oven temp 60°C, flow rate 1.0 mL/min. Initial temperature was maintained at 40°C for 5 minutes, and the rate was maintained at 10°C/min until it reached 310°C.

According to the results of the intestinal microflora analysis, Ecklonia cava extract was shown to protect the intestinal tract by increasing the beneficial bacteria in the intestine. Accordingly, short-chain fatty acids (acetate, propionate, butyrate), which are beneficial intestinal metabolites, were measured ( FIG. 4 ). In the PM _2.5 exposure group (acetate; 79.43%, propionate; 82.38%), the normal control group (100.00%) showed decreased acetate and propionate. On the other hand, the Ecklonia cava extract diet group (acetate; 119.68%, propionate; 113.30%, butyrate; 171.82%) showed a very high short-chain fatty acid content even when compared with the normal control group ( FIGS. 4a and 4b ).

[Example 3] Analysis of major physiologically active substances of Ecklonia cava extract

3.1 Determination of total polysaccharide content

The total polysaccharide content contained in the Ecklonia extract was measured by modifying the phenol-sulfuric acid method. 5% phenol solution and concentrated sulfuric acid were added to the extract, and the absorbance was measured at 470 nm after leaving it at room temperature for 20 minutes. A standard curve was prepared using the standard substance glucose, substituted and calculated.

The results of measuring the total polysaccharide content and constituents (sulfate and constituent sugar) of the Ecklonia extract are shown in Table 3 below. The total polysaccharide content was found to be 34.26%.

Total polysaccharide (%) Mw (kDa) sulfate (%) Relative Area (%) Fucose Rhamnose Galactose Glucose Xylose Others 34.26 160.13 17.03 9.76 16.03 6.53 6.65 48.97 12.06

3.2 Measure average molecular weight (Mw)

The average molecular weight of the Ecklonia extract was measured using gel permeation chromatography (HLC-8320, Tosoh Bioscience, Stuttgart, Germany). The sample was dissolved in distilled water and filtered through a 0.45 μm Nylon filter (Millipore Co., Bedford, MA, USA). Using a column combined with Tskgel guard PWxl, 2 x TSKgel GMPWxl, and TSKgel G2500PWxl (7.8 x 300 mm, Tosoh Bioscience, Stuttgart, Germany), 0.1 M NaNO ₃ as a mobile phase was analyzed with an RI-detector at 1 mL/min. .

The results of measuring the total polysaccharide content and constituents (sulfate and constituent sugar) of the Ecklonia extract are shown in Table 3 above. The average molecular weight was found to be 160.13 kDa.

3.3 Determination of Sulfate Content

To 0.2 mL of the test solution, 3.8 mL of 4% TCA solution and 1 mL of BaCl ₂ -gelatin reagent were added, stirred and left for 20 minutes, and then absorbance was measured at 360 nm. A standard calibration curve was prepared using K ₂ SO ₄ to quantify the content of sulfate groups.

The results of measuring the total polysaccharide content and constituents (sulfate and constituent sugar) of the Ecklonia extract are shown in Table 3 above. Sulfate content was found to be 17.03%.

3.4 Analysis per component

The analysis of constituent sugars contained in the Ecklonia extract was measured using the HPAEC-PAD system (Dionex, Sunnyvale, CA, USA). The sample was hydrolyzed with trifluoroacetic acid, lyophilized, dissolved in distilled water, and filtered through a 0.45 μm membrane filter (Millipore Co., Bedford, MA, USA). Using a CarboPacTM PA1 column (0.4 X 25 cm, Dionex, Sunnyvale, CA, USA), 18 mM NaOH/200 mM NaOH as a mobile phase was analyzed with an RI detector at 1 mL/min. Identification and confirmation of constituent sugars were shown by comparing and verifying retention time (Rt) of saccharide standards (Fucose, Rhamnose, Galactose, Glucose, Xylose).

The results of measuring the total polysaccharide content and constituents (sulfate and constituent sugar) of the Ecklonia extract are shown in Table 3 above. The relative proportion of constituent sugars was in the order of xylose (48.97%) > rhamnose (16.03%) > fructose (9.76%) > glucose (6.65%) > galactose (6.53%).

3.5 Analysis of Phenolic Compounds

UPLC IMS-QTOF/MS (Vion, Waters, Milford, MA, USA) was used to identify major physiologically active substances of Ecklonia extract. After dissolving the sample in methanol, it was filtered using a 0.2 μm filter. C18 column (100×2.1 mm, 3.5 μm, Agilent, Santa Clara, CA, USA) was used for the column, and tertiary distilled water (A) mixed with 0.1% formic acid and acetonitrile (B) were used as the mobile phase solvent. and the ratio of solvent B was as follows: 0.1-25% 0-2 minutes, 25-50% 2-8 minutes, for a total of 8 minutes. Using the negative ion mode of electrospray ionization (ESI), it was performed under the following conditions: sample temperature, 100 °C; desolvation line temperature. 400°C; lamp collision energy. 10-30V; Capillary voltage, 2.5 kV. The detected phenolic compounds were analyzed within the range of 50-1500 m/z.

The results of analysis of phenolic compounds as major physiologically active substances of Ecklonia extract are shown in FIG. 5 and Table 4 below. The major phenolic compounds of Ecklonia extract are phlorotannin-based substances with phloroglucinol as the basic structure (Tetraphloroetiol isomer, Eckol, 2′-phloroeckol, 6′6′-bieckol, dieckol, phlorofuroeckol A, 2,7″-phloroglucinol 6,6 '-bieckol, 974-A) were detected. Among them, Peak 1 (2.60 min); tetraphloroetiol isomer (phloroglucinol tetramer; m/z 497.11278; 327, 265, 231, 139) and Peak 4 (3.25 min); 2'-phloroeckol (m/z 495.09875; 477, 387, 263, 244, 231, 229, 201) was analyzed to have the highest content.

No. RT (min) m/z
[MH] ^- MS ² fragments Proposed compounds One 2.60 497.11278 327, 265, 231, 139 isometric tetramer (phlorotannin oligomer) 2 2.93 497.11278 371, 353, 231, 229, 138, 125 isometric tetramer (phlorotannin oligomer) 3 3.21 371.04088 353, 263, 245, 201 Eckol 4 3.25 495.09875 477, 387, 263, 244, 231, 229, 201 2-Phloroeckol 5 3.34 741.13508 723, 490, 477, 244, 229, 201 6'6'-Bieckol 6 3.62 741.13508 615, 493, 491, 477, 369, 261, 229, 201 Dieckol 7 3.79 601.11104 493, 492, 385, 366, 244, 299 Phlorofuroeckol A 8 4.13 973.19218 741, 602, 601, 493, 370, 229 2,7''-Phloroglucinol 6,6'-bieckol (PHB) 9 4.25 973.19218 829, 707, 493, 479, 353, 335, 229 974-A 10 6.91 642.4498 363, 362, 279, 99, 85 Unknown

[Example 4] Statistical processing

All experiments were expressed as mean±SD after repeated runs. The statistical significance of the experimental results was calculated by one-way analysis of variance (ANOVA) using SAS software (version 9.1, SAS Institute Inc., Cary, NC, USA). (Duncan's new multiple-range test) verified the significant difference at the 5% level ( p <0.05).

So far, the present invention has been looked at with respect to preferred embodiments thereof.

Those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated in the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.

Claims (14)

A health functional food composition for preventing and improving intestinal diseases caused by fine dust, comprising Ecklonia cava extract as an active ingredient. The method of claim 1,
The extract is a functional health food composition for preventing and improving intestinal diseases caused by fine dust, characterized in that it is extracted by water or organic solvent extraction method. 3. The method of claim 2,
The organic solvent extraction method is a health functional food composition for preventing and improving intestinal diseases caused by fine dust, characterized in that 30 to 80% ethanol is used. The method of claim 1,
The intestinal disease is characterized in that the intestinal disease, and the intestinal disease is any one of irritable bowel syndrome, Crohn's disease, ulcerative colitis, chronic constipation and short bowel syndrome, preventing and improving intestinal diseases caused by fine dust. Functional food composition. The method of claim 1,
The composition is a health functional food composition for preventing and improving intestinal diseases caused by fine dust, characterized in that it increases the weight and food amount reduced due to exposure to fine dust. According to claim 1,
The composition is a health functional food composition for preventing and improving intestinal diseases caused by fine dust, characterized in that it restores the length of the large intestine reduced due to exposure to fine dust. The method of claim 1,
The composition is a health functional food composition for preventing and improving intestinal diseases due to fine dust, characterized in that it reduces the moisture content of the feces increased due to exposure to fine dust. The method of claim 1,
The composition is a health functional food composition for preventing and improving intestinal diseases caused by fine dust, characterized in that it changes the microflora of the intestinal tract. 9. The method of claim 8,
The change in the flora of the intestinal microflora increases the Lactobacillaceae , which was reduced due to fine dust, and reduces the Rikenellaceae , which was increased due to the fine dust, Odoribacteraceae , which was increased due to the fine dust. Erysipelotrichia, which was increased due to fine dust ( Erysipelotrichaceae ) to reduce, enterobacteriaceae increased due to fine dust ( Enterobacteriaceae ) to reduce, reduce the Eubacteriaceae ( Eubacteriaceae ) increased due to fine dust, and to reduce the Bacillaceae ( Bacillaceae ) that was increased due to fine dust For preventing and improving intestinal diseases caused by fine dust A health functional food composition. 9. The method of claim 8,
The change in the flora of the intestinal microflora increases the genus Lactobacillus, which has been reduced due to fine dust, and increases the genus Lactobacillaceae_uc , which has been reduced due to fine dust, and the genus Aristipes increased due to fine dust ( Alisipes ) to reduce, Pseudoflavonifractor , which was increased due to fine dust, to decrease, and Odoribacter , which was increased due to fine dust Reducing the genus Sporobacter and increasing the genus Caproic ai producens due to fine dust ( Caproiciproducens ) A health functional food composition for preventing and improving intestinal diseases caused by fine dust, characterized in that it reduces the genus Escherichia , which was increased due to fine dust. The method of claim 1,
The composition is a health functional food composition for preventing and improving intestinal diseases due to fine dust, characterized in that it increases the short-chain fatty acids reduced due to exposure to fine dust. In a food composition for preventing and improving intestinal diseases caused by fine dust, comprising an E. coli extract as an active ingredient, the intestinal disease is characterized in that the intestinal disease, the intestinal disease is irritable bowel syndrome, Crohn's disease, ulcerative colitis, Any one of chronic constipation and short bowel syndrome, the food composition. In the pharmaceutical composition for the prevention and treatment of intestinal diseases caused by fine dust, comprising an E. coli extract as an active ingredient, the intestinal disease is characterized in that the intestinal disease, the intestinal disease is irritable bowel syndrome, Crohn's disease, ulcerative colitis , which is any one of chronic constipation and short bowel syndrome, a pharmaceutical composition. In the cosmetic composition for preventing and improving intestinal disease caused by fine dust, comprising an Ecklonia extract as an active ingredient, the intestinal disease is characterized in that the intestinal disease, the intestinal disease is irritable bowel syndrome, Crohn's disease, ulcerative colitis, Any one of chronic constipation and short bowel syndrome, the cosmetic composition.

Images